As per the final data, submitted after a small mid-stage trial by the company, Amgen's bone medicine denosumab successfully manages to stop progressive bone destruction and rapid spreading of tumors in some patients suffering from a rare kind of non-malignant bone cancer.

With the data, which has been the first to clearly reveal that there is a promising treatment option for rare and inoperable Giant-Cell Tumors (GCTs), further statistics have been added to recent positive results for the medicine, which is being viewed as an important sales drives for the American biotechnology firm.

Denosumab, which is also known by the brand name Prolina, is the first in a new class which has specifically been designed to inhibit proteins that work towards the activation of cells that destroy bones.

The trial of the medicine included 37 patients with non-malignant GCT from across the US, Australia and Europe. They were given monthly shots of the new drug, in addition to doses on first month's days 8 and 15. Results then revealed that 86% of the patients had responded to the drug, while 84% reported benefits like reduced pain and better mobility and 26% had bone repair.